11 C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine, is a new positron emission tomography (PET) radioligand with high affinity and selectivity for the serotonin transporter (SERT). The purpose of this study was to determine the most appropriate kinetic model to quantify [11 C]AFM binding in the healthy human brain. Positron emission tomography data and arterial input functions were acquired from 10 subjects. Compartmental modeling and the multilinear analysis-1(MA1) method were tested using the arterial input functions. The one-tissue model showed a lack of fit in low-binding regions, and the two-tissue model failed to estimate parameters reliably. Regional time-activity curves were well described by MA1. The rank order of
INTRODUCTIONThe serotonin transporter (SERT) is located on the presynaptic terminals of neurons, and is responsible for the reuptake of serotonin, a neurotransmitter involved in the regulation of brain functions such as mood, appetite, and sleep.1 Serotonin transporter is a primary target of action for selective serotonin reuptake inhibitors, which are effective therapeutic agents for the treatment of major depressive disorder, obsessive-compulsive disorder, posttraumatic stress disorder, and other mood and anxiety disorders. Because the serotonin system has such an important role in the pathophysiology of these diseases, there has been considerable interest in developing in vivo positron emission tomography (PET) radioligands for imaging SERT distribution. In the human brain, highest concentrations of SERT are found in the raphe nucleus and midbrain, followed by thalamus, striatum, and amygdala. Intermediate levels are in the limbic system (hippocampus and cingulate cortex), and lower levels in the neocortex regions, with cerebellum displaying lowest to negligible SERT density.